NCT00068718View on ClinicalTrials.gov

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell Myeloma
Interventions
BIOLOGICAL

Therapeutic Allogeneic Lymphocytes

Given IV

Trial Locations (4)

10126

University of Torino, Torino

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

D-04103

Universitaet Leipzig, Leipzig

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00068718 - Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | Biotech Hunter | Biotech Hunter